Quantum-Si Incorporated (Nasdaq: QSI), known as The Protein Sequencing Company, has announced the addition of Paula Dowdy to its Board of Directors. Dowdy, a seasoned executive with over 35 years of experience spanning life sciences, enterprise software, and technology, brings a wealth of expertise to Quantum-Si.
Before joining Quantum-Si’s board, Dowdy served on the Board of Directors for SPT Labtech and worked as an advisor at EQT Life Sciences. She previously held the position of SVP and General Manager of Europe, Middle East, and Africa (EMEA) at Illumina, where she played a pivotal role in doubling the company’s EMEA business. Prior to Illumina, Dowdy spent over two decades at Cisco Systems, Inc., holding various leadership roles globally.
Jeff Hawkins, President, and CEO of Quantum-Si, expressed excitement about Dowdy’s appointment, highlighting her successful track record in driving growth and innovation in genomics and technology. He emphasized Dowdy’s experience in market development and global operations, which aligns with Quantum-Si’s mission to revolutionize protein sequencing and improve human health.
Dowdy herself expressed her honor in joining Quantum-Si’s Board of Directors, acknowledging the company’s groundbreaking technology and its potential to transform proteomics in treating complex diseases. She emphasized her commitment to supporting Quantum-Si as it continues to expand its reach and impact in the field of proteomics.
Dowdy holds an MBA from Pepperdine University and a Bachelor of Arts degree from the University of California, Berkeley. Her appointment to Quantum-Si’s Board of Directors is effective immediately.
